If you thought roll-up mergers expanding into new lines had gone the way of concentrating on core operations, guess again.  Playtex Products Inc. (NYSE:PYX) is being acquired by Energizer...
Crude oil refiners Sunoco (NYSE:SUN) and Western Refining (NYSE:WNR) reported earnings this morning before the market opened.  Sunoco posted diluted EPS of $4.70 on revenues $16.109 billion. Western...
OSI Pharmaceuticals Inc. (NASDAQ: OSIP) is getting hit hard in early trading this morning.  The biotech has released data showing that a Phase III trial of Genentech’s (NYSE: DNA) Avastin combined...
The hope for a higher Genentech Inc. (NYSE: DNA) buyout price is getting smaller and smaller.  After the companies agreed to a $95.00 per share merger, this was already assumed as the nearly certain...
Applied DNA Sciences shares shot up on Monday after the company announced an update to its COVID-19 vaccine program.
Independent oil & gas company Harvest Natural Resources Inc. (NYSE: HNR) announced on Friday an “at-the-market” equity financing program that would allow the company to issue up to $75 million in...
Western Refining, Inc. (NYSE: WNR) has announced its intent to sell 14 million shares of common stock.  This would bring in gross proceeds of nearly $196 million at current prices.  The company...
In the wake of a poor first quarter report, iron ore producer Cliffs Natural Resources Inc. (NYSE:CLF), formerly known as Cleveland-Cliffs, has tightened its belt and the belts of all its...
Before Roche decided to try to buy the 44% of biotech company Genentech (DNA) that it did not already own the smaller firm traded at $75. Roche offered just over $86 a share. Genentech said...
Newly-named Cliffs Natural Resources Inc. (NYSE:CLF) is slowing production at two of its Minnesota iron ore mines in order "to bring production in line with demand." Three furnaces capable of...
The proposed merger between Cliffs Natural Resources (NYSE:CLF) and Alpha Natural Resources (NYSE:ANR) has run over more than a few bumps. Cliffs’ largest shareholder, Harbinger Capital, tried to...
Genentech Inc. (NYSE:DNA) is set to report earnings after today’s close. First Call has consensus estimates at $0.72 EPS on $2.93 Billion in revenues.  The biotech giant usually offers...
Genentech (DNA) Big biopharma drops on poort clinical trial results for its drug Avastin. Down to $75.56 from 52-week high of $89.73. Verasun Energy (VSE) Rise in supply of ethanol could hurt...
MBIA (MBI) Downgrade by Moody’s. Falls to $25.84 from 52-week high of $76.02. Genentech (DNA) FDA rejects key drug. Drops to $65.54 from 52-week high of $89.73. AMD (AMD) More analyst concerns....